Foghorn Therapeutics Shares Rally Premarket as FDA Lifts Clinical Hold
05 Junho 2023 - 9:07AM
Dow Jones News
By Colin Kellaher
Foghorn Therapeutics shares rose sharply in premarket trading
Monday after the clinical-stage biotechnology company said the U.S.
Food and Drug Administration has lifted a clinical hold on a study
of its FHD-286.
The Cambridge, Mass., company said it expects to launch a Phase
1 study of FHD-286 in the third quarter.
Foghorn last August said the FDA had placed a full clinical hold
on the Phase 1 monotherapy dose escalation study of FHD-286 in
acute myelogenous leukemia and myelodysplastic syndrome due to
suspected cases of fatal differentiation syndrome believed to be
associated with FHD-286 treatment.
The company said it has amended the trial protocol, and that it
now plans to study FHD-286 in combination with decitabine or
cytarabine in relapsed and/or refractory acute myelogenous leukemia
patients .
Foghorn shares, which closed Friday at $7.10, were recently up
more than 18% to $8.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2023 07:52 ET (11:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Foghorn Therapeutics (NASDAQ:FHTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Foghorn Therapeutics (NASDAQ:FHTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
